Thus, BRM might become a crucial remaining ATPase maintaining the expression of MITF and perhaps additional new targets described here in melanoma cells in vivo under conditions of BRG1 loss [26], especially in later stages of tumor progression. The gene discussed is SMARCA2; the disease is melanoma.